



## Correction: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

The article by de Velasco and colleagues that was published in the April 2017 issue of *Cancer Immunology Research* (1) incorrectly reported the treatment arms of one clinical trial in Fig. 1 and Table 1. The corrected figure and table appear below. These changes do not alter the main conclusions of this study, nor do they affect the statistical analyses in the article, as the correct number of patients in each group (anti-PD-1/PD-L1 or anti-CTLA-4) was used in all instances. The authors regret these errors and thank Si-Cong Jiang, Fei-fei Zhang, and Jian-Jun Tang for their detection of them. The online version of the article has been updated to reflect the content of this correction.




Figure 1.

**Table 1.** List of clinical trials included in the meta-analysis

Reference	Ph	Tumor type	No.	Treatment arms	Colitis		Increased AST		Rash		Hypothyroidism		Pneumonitis		
					Grade	Grade	Grade	Grade	Grade	Grade	Grade	Grade			
Ipilimumab															
1	Beer et al. 2016 (1)	3	Prostate	602	Ipilimumab	N/A	N/A	N/A	N/A	132	10	N/A	N/A	1	1
					Placebo	N/A	N/A	N/A	N/A	15	0	N/A	N/A	N/A	N/A
2	Reck et al. 2016 (2)	3	SCLC	1132	VP16 + Plt con Ipi	29	24	N/A	N/A	90	N/A	14	N/A	N/A	N/A
					VP16 + Plt + Placebo	N/A	N/A	N/A	N/A	14	N/A	N/A	N/A	N/A	N/A
3	Eggermont et al. 2016 (3)	3	Melanoma	951	Ipilimumab	75	36	78	20	162	6	42	1	N/A	N/A
					Placebo	6	1	24	0	52	0	4	0	N/A	N/A
4	Kwon et al. 2014 (4)	3	Prostate	799	Ipilimumab	27	18	22	9	68	2	9	2	5	1
					Placebo	3	0	13	4	16	0	1	0	0	0
5	Reck et al. 2013 (5)	2	SCLC	130	CP	N/A	N/A	14	0	1	0	N/A	N/A	N/A	N/A
					CP + Con Ipi	N/A	N/A	21	5	15	2	N/A	N/A	N/A	N/A
					CP + Seq Ipi	N/A	1	17	3	10	0	N/A	N/A	N/A	N/A
6	Lynch et al. 2012 (6)	2	NSCLC	204	CP	N/A	N/A	34	2	10	2	N/A	N/A	N/A	N/A
					CP + Con Ipi	N/A	N/A	27	2	28	3	N/A	N/A	N/A	N/A
					CP + Seq Ipi	N/A	2	33	2	13	3	N/A	N/A	N/A	N/A
7	Robert et al. 2011 (7)	3	Melanoma	502	Ipi + DTIC	11	5	66	43	55	3	4	0	N/A	N/A
					Dacarbazine	0	0	8	1	12	0	1	0	N/A	N/A
8	Hodi et al. 2010 (8)	3	Melanoma	676	Ipi + Gp100	20	12	4	1	67	5	6	1	N/A	N/A
					Ipilimumab	10	7	1	0	25	1	2	0	N/A	N/A
					Gp100	1	0	2	0	6	0	2	0	N/A	N/A
Nivolumab															
9	Ferris et al. 2016 (9)	3	Head and Neck	361	Nivolumab	0	0	2	0	18	0	9	0	5	2
					Chemotherapy	1	0	2	0	5	1	1	0	1	0
10	Robert et al. 2015 (10)	3	Melanoma	518	Nivolumab	2	1	2	1	31	1	9	0	3	0
					Dacarbazine	0	0	4	1	6	0	1	0	0	0
11	Weber et al. 2015 (11)	3	Melanoma	405	Nivolumab	5	2	12	1	35	1	15	0	5	0
					Chemotherapy	0	0	2	0	12	0	0	0	0	0
12	Brahmer et al. 2015 (12)	3	NSCLC	272	Nivolumab	1	1	2	0	5	0	5	0	6	1
					Docetaxel	0	0	1	0	8	2	0	0	0	0
13	Borghaei et al. 2015 (13)	3	NSCLC	582	Nivolumab	2	1	9	1	36	1	19	0	8	3
					Docetaxel	0	0	2	0	13	0	0	0	1	1
14	Motzer et al. 2015 (14)	3	RCC	821	Nivolumab	N/A	N/A	N/A	N/A	41	2	N/A	N/A	16	6
					Everolimus	N/A	N/A	N/A	N/A	79	3	N/A	N/A	58	11
Pembrolizumab															
15	Herbst et al. 2016 (15)	3	NSCLC	1034	Pembro 2 mg	4	3	10	2	29	1	28	0	16	7
					Pembro 10 mg	2	1	7	0	44	1	28	0	15	7
					Docetaxel	0	0	3	0	14	0	1	0	6	2
16	Langer et al. 2016 (16)	2	NSCLC	123	CPem + con/seq	N/A	N/A	11	1	1	1	9	0	3	1
					Pembrolizumab	N/A	N/A	7	1	1	1	3	0	0	0
17	Reck et al. 2016 (17)	3	NSCLC	305	Pembrolizumab	3	2	N/A	N/A	6	6	14	0	9	4
					Chemotherapy	0	0	N/A	N/A	0	0	2	0	1	1
18	Ribas et al. 2015 (18)	2	Melanoma	540	Pembro 2 mg	2	0	N/A	N/A	21	0	9	0	3	0
					Pembro 10 mg	3	2	N/A	N/A	18	0	13	0	3	2
					Chemotherapy	1	1	N/A	N/A	8	0	0	0	0	0
19	Bellmunt et al. 2016 (19)	3	Bladder	542	Pembrolizumab	6	3 <sup>a</sup>	N/A	N/A	2	1 <sup>a</sup>	N/A	N/A	11	6 <sup>a</sup>
					Chemotherapy	1	0	N/A	N/A	3	3	N/A	N/A	1	0
Atezolizumab															
20	Fehrenbacher et al. 2016 (20)	2	NSCLC	287	Atezolizumab	2	1	6	3	N/A	N/A	9	1 <sup>a</sup>	4	1
					Docetaxel	N/A	N/A	N/A	N/A	N/A	N/A	0	0	N/A	N/A
21	Rittmeyer et al. 2016 (21)	3	NSCLC	1125	Atezolizumab	2	0	N/A	N/A	N/A	N/A	N/A	N/A	6	4
					Docetaxel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Abbreviations: Con, concurrent; CP, carboplatin/paclitaxel; CPem, carboplatin/pemetrexed; DTIC, dacarbazine; gp100, glycoprotein 100; hypoT, hypothyroidism; Mos, months; No., number of patients; Pembro, pembrolizumab; Plt, platinum salt; Seq, sequential; Tx, treatments; VP16, etoposide.

<sup>a</sup>Proportion of high-grade adverse events estimated from study's band diagram.

## Reference

- de Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. *Cancer Immunol Res* 2017;5:312–8.

Published first March 20, 2018.

doi: 10.1158/2326-6066.CIR-18-0078

©2018 American Association for Cancer Research.